CD44 - BP25385 (Principal Investigator: prof. dr. H.M.W. Verheul)
Open-Label Multicenter 2-Arm Phase I Study of RO5429083 with Dose-Escalation and Extension Cohorts, and Imaging Cohorts with RO5429083 and 89Zr-labeled RO5429083, in Patients with Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors.
Vectibix (Panitumumab) (Principal Investigator: prof. dr. H.M.W. Verheul)
Chemoradiation with gemcitabine in combination with panitumumab for patients with locally advanced pancreatic cancer.
LMWH Dalteparin (Principal Investigator: prof. dr. H.M.W. Verheul )
Phase I/II study of dalteparin, a low molecular weight heparin (LMWH), in combination with Sunitinib (SU11248), an oral, selective multitargeted tyrosine kinase inhibitor, as first line treatment, in patients with metastatic renal cell carcinoma.
NY-ESO-1 (Principal Investigator: dr. A.J.M. van den Eertwegh)
An open Phase I Study of immunization with the recNY-ESO-1 + AS15 Antigen-Specific Cancer Immunotherapeutic in patients with NY-ESO-1- positive unresectable and progressive metastatic cutaneous melanoma.
Everolimus_LDcycle (Principal Investigator: dr. J.J. van der Vliet)
Phase 1-2 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
2B3-101-CR-001 (Principal Investigator: prof. dr. H.M.W. Verheul)
An open-label, Phase I/IIa, dose escalating study of 2B3-101 in patients with solid tumors and brain metastases or recurrent malignant glioma.
Pilot ICK (Principal Investigator: prof. dr. H.M.W. Verheul / drs. M. Labots)
Pilot study on the determination of intratumoral concentrations of kinase inhibitors in patients with advanced solid malignancies.
Releasing the brakes (Principal Investigator: dr. A.J.M. van den Eertwegh)
Releasing the brakes on CD8+ T cells in the melanoma sentinel lymph node by pre-operative local administration of low-dose anti-CTLA-4 (tremelimumab).
EORTC 26053-22054 (Principal Investigator: dr. J. Reijneveld / dr. J. Buter)
Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial.
LUX Head & Neck 2 (Principal Investigator: dr. J. Buter)
A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinoma.
Abiraterone Breast (Principal Investigator: prof. dr. E. Boven)
Randomized, Open-Label Study of Abiraterone Acetate (JNJ-212082) plus Prednisone/Prednisolone with or without Exemestane in Postmenopausal Women with ER+ Metastatic Breast Cancer Progressing after Letrozole or Anastrozole Therapy.
PHEREXA - MO22324 (Principal Investigator: prof. dr. E. Boven)
A multicenter randomized phase II study to compare the combination trastuzumab and capecitabine, with or without pertuzumab, in patients with HER2-positive metastatic breast cancer that have progressed after one line of trastuzumab-based therapy in the metastatic setting.
TEAMIIb (Principal Investigator: prof. dr. E. Boven)
A randomised, multicentre, prospective phase II trial investigating the efficacy and safety of the addition of ibandronate to adjuvant hormonal therapy in postmenopausal women with hormone receptor positive early breast cancer.
PACES (A-CaRe 2) (Principal Investigator: prof. dr. E. Boven)
A-CaRe study 2: PACES (Physical exercise during Adjuvant Chemotherapy Effectiveness Study).
PROSPECT (Principal Investigator: prof. dr. E. Boven)
Nature and mechanism of cognitive deficits following chemotherapy: an (f)MRI study.
PACES (A-CaRe 2) (Principal Investigator: prof. dr. E. Boven)
A-CaRe study 2: PACES (Physical exercise during Adjuvant Chemotherapy Effectiveness Study).
COLO CETUX (Principal Investigator: prof. dr. H.M.W. Verheul, Trial coordinator: dr. C.W. Menke- van der Houven van Oordt)
Treatment optimization of cetuximab in patients with metastatic colorectal cancer based on tumor uptake of 89Zr-labeled cetuximab assessed by PET.
Vectibix (Panitumumab) (Principal Investigator: prof. dr. H.M.W. Verheul)
Chemoradiation with gemcitabine in combination with panitumumab for patients with locally advanced pancreatic cancer.
AMG479 (Principal Investigator: prof. dr. H.M.W. Verheul)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Trial of AMG 479 or Placebo in Combination with Gemcitabine as First-line Therapy for Metastatic Adenocarcinoma of the Pancreas.
GEM/CIS/VIT (Principal Investigator: dr. J.J. van der Vliet)
Randomized Phase 2 study with Gemzar and Cisplatin combination with or without Vitamin Supplementation in patients with advanced esophagogastric cancer.
CRITICS (Principal Investigator: prof. dr. H.M.W. Verheul)
ChemoRadiotherapy after Induction chemoTherapy In Cancer of the Stomach A multicenter randomised phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer.
NARCIS (Principal Investigator: prof. dr. H.M.W. Verheul)
Neo-Adjuvant Radiotherapy-Chemotherapy in Stomach Cancer. Induction therapy with carboplatin, paclitaxel and radiotherapy in patients with locally advanced gastric cancer. The "NARCIS" study, a phase I/II study.
Currently there are no clinical trials open for inclusion for patients with liver tumors.
Recardo (Principal Investigator: prof. dr. W. Gerritsen)
A randomized phase II trial of docetaxel plus carboplating versus docetaxel in hormone refractory prostate cancer patients who have progressed after response to prior tocetaxel chemotherapy.
CA184-095 (Principal Investigator: prof. dr. W. Gerritsen)
Randomized, double-blind, phase 3 trial to compare the efficacy of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naïve castration resistant prostate cancer.
Healthy men vs. prostate cancer patients (Principal Investigator: dr. A.J.M. van den Eertwegh)
Monitoring of DC and T cell functions in patients with prostate cancer treated with GM-CSF transduced allogeneic vaccines and anti-CTLA-4.
CUP Abiraterone Acetate (Contact person: dr. A.J.M. van den Eertwegh / prof. dr. W. Gerritsen)
Compassionate Use Programme Abiraterone Acetate.
LMWH Dalteparin (Principal Investigator: prof. dr. H.M.W. Verheul )
Phase I/II study of dalteparin, a low molecular weight heparin (LMWH), in combination with Sunitinib (SU11248), an oral, selective multitargeted tyrosine kinase inhibitor, as first line treatment, in patients with metastatic renal cell carcinoma.
Everolimus_LDcycle (Principal Investigator: dr. J.J. van der Vliet)
Phase 1-2 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.
CRT vulva (Principal Investigator: prof. dr. H.M.W. Verheul)
Phase II study of definitive radiochemotherapy for locally advanced squamous cell cancer of the vulva: an efficacy study.
E55994 (Principal Investigator: prof. dr. H.M.W. Verheul)
Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. Concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer.
PORTEC3 (Principal Investigator: prof. dr. H.M.W. Verheul)
Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma: PORTEC-3.
MORAb-003-004 (Principal Investigator: prof. dr. H.M.W. Verheul)
A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Platinum-sensitive Ovarian Cancer in First Relapse.
BRAF EAP (Principal Investigator: dr. A.J.M. van den Eertwegh)
An open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma.
TEAM trial (Principal Investigator: dr. A.J.M. van den Eertwegh)
The TEAM trial (Tasigna efficacy in advanced melanoma): A randomized, phase III, open label, multi-center, two-arm study to compare the efficacy of Tasigna® versus dacarbazine (DTIC) in the treatment of patients with metastatic and/or inoperable melanoma harboring a c-Kit mutation.
NY-ESO-1 (Principal Investigator: dr. A.J.M. van den Eertwegh)
An open Phase I Study of immunization with the recNY-ESO-1 + AS15 Antigen-Specific Cancer Immunotherapeutic in patients with NY-ESO-1- positive unresectable and progressive metastatic cutaneous melanoma.
Releasing the brakes (Principal Investigator: dr. A.J.M. van den Eertwegh)
Releasing the brakes on CD8+ T cells in the melanoma sentinel lymph node by pre-operative local administration of low-dose anti-CTLA-4 (tremelimumab).
ABP-Statins (Principal Investigator: dr. J.J. van der Vliet)
Effect of aminobiphosphonates and statins on circulating Vgamma9Vdelta2-T cells.
Use of oral oncolytic drugs (Sub-investigator: Prof. dr. E. Boven)
Adherence and patients' experiences with oral anticancer agents.
BeCet (Principal Investigator: prof. dr. E. Boven)
Phase III Randomized Double-Blind Trial of Bepanthen® Cream Versus Cetomacrogol Cream in the Prevention of Papulopustular eruption in Patients Receiving Epidermal Growth Factor Receptor Inhibitors (EGFRI): BeCet
Pilot ICK (Principal Investigator: prof. dr. H.M.W. Verheul / drs. M. Labots)
Pilot study on the determination of intratumoral concentrations of kinase inhibitors in patients with advanced solid malignancies.
(Pre)cachexie prevalence (Principal Investigator: M. van Bokhorst / S. Buskermolen)
Prevalence and biomarkers of pre-cachexia and cachexia in advanced cancer patients scheduled for treatment with chemotherapy.
Cytofys+ (Principal Investigator: not applicable)
Cytostatics and physiotherapy.
Delirium study (Principal Investigator: prof. dr. H.M.W. Verheul/dr. M. van der Vorst)
Early Recognition and Optimal Treatment of Delirium in Patients with Advanced Cancer.
For more information regarding participation in a clinical trial please contact your treating physician.
For referral of patients for participation in a clinical trial please contact the Principal Investigator at tel. +31 20 444 1295.